Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo Holdings to make an investment in Biocomposites ("the Company"), an international ...

Novo Holdings and TA Associates have agreed to make an investment into Biocomposites.

Additional investment and resources will accelerate Biocomposites' international expansion and innovation in products for use in infection management HELLERUP, Denmark, LONDON and KEELE ...

A medical device company has secured investment from the owner of the developer of Ozempic and a private equity firm, to ...

Callio Therapeutics, which has dual headquarters in Seattle and Singapore, launched Monday with a $187 million Series A round ...

In conjunction with the financing, Callio Therapeutics has entered into an exclusive worldwide license agreement with Hummingbird Bioscience for its multi-payload ADC platform in oncology, and ...

Callio Therapeutics, a biotechnology company, has launched with the closing of a $187.0 million Series A financing round.

Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...

Frazier Life Sciences launched Callio Therapeutics, a cancer startup headquartered in Seattle and Singapore. Frazier led ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...